Trial
TULIP-2
Anifrolumab improved composite disease activity in SLE.
Sparsely connected — only 1 link recorded so far.
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 1 and is affected by 0 concepts — mostly 1 therapy.
- 3Where it sits: trial on the 15-step immune chain.
Its connections at a glance
Each dot is a concept directly linked to TULIP-2. Colours show the kind of concept.
Learn next
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR021 · concept status: established. Select any connection above to inspect evidence for that specific link.